Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Goldline Pharmaceutical IPO
Price Band
₹41.0–43.0
Issue Size
₹11.61 Cr
Lot Size
3,000 shares
Min Investment
₹258,000
2 LOTS MIN
GMP
+₹15.0 (34.88%)
Issue Price
₹43.0
Goldline Pharmaceutical IPO AI Summary
- Goldline Pharmaceutical IPO is listed on BSE SME in the Pharmaceuticals sector.
- Price band: ₹41.0–₹43.0 per share, lot size 3,000 shares (min. investment ₹258,000, 2 lots minimum).
- Subscription window: 12 May–14 May 2026, listing on 19 May 2026.
- Current GMP is +₹15.0 (34.88%), an estimated listing price of ₹58 — unofficial and can change daily.
Goldline Pharmaceuticals is preparing for its IPO with a price band of ₹41.0 to ₹43.0, aiming to raise ₹11.61 Cr. The company has shown growth in total income and profit over recent periods, although the latest figures are for a 9-month period and not directly comparable to full-year results.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Goldline Pharmaceutical IPO Grey Market Premium (GMP) Today
GMP
+₹15.0
GMP %
+34.88%
Est. Listing
₹58.0
Updated: 14 Jul 2026 15:52
About the Company
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments: Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. Goldline Cardinal: This category offers 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians. Goldline Aayushman: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners. Goldline InLife: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians. Goldline Wellness: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy. The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations. All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply. The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Competitive Strengths: Experienced Promoters and Management Team with Industry Knowledge and a Track Record Asset-light Business Model and Competitive Products Scalable Business Model Wide and Diverse Range of Product Offerings Strong Supplier and Vendor Relationships Established Distribution Network
Company Financials (₹ Cr)
As of 2025-12-31
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total Income | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| EBITDA | 4.16 | 5.83 | 4.30 | 2.19 |
| NET Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves and Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
Key Ratios
EPS
₹4.11
NAV
₹12.38
ROE
35.83%
ROCE
38.45%
RoNW
27.37%
P/B Value
3.47
P/E Ratio
10.47
Market Cap
₹41.28 Cr
PAT Margin
10.09%
Debt/Equity
1.50
Promoters
Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company 8.35 2 General Corporate Purposes 1.71 3 Issue Expense 1.55 Total 11.61
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹19.85 Cr in the year ended 31 Mar 2023, rising to ₹23.57 Cr by 31 Mar 2024, then increasing further to ₹28.06 Cr by 31 Mar 2025. However, total income decreased to ₹21.41 Cr by 31 Dec 2025, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹0.26 Cr in the year ended 31 Mar 2023, increasing to ₹1.81 Cr by 31 Mar 2024. This rose to ₹2.83 Cr by 31 Mar 2025, but then decreased to ₹2.22 Cr by 31 Dec 2025, though this is a 9-month figure, not a full year, so isn't directly comparable.
Grey Market Premium, Explained
The Grey Market Premium (GMP) is an indicator of the expected listing price of an IPO. It reflects the price at which shares are being traded in the unofficial market before they are listed on the stock exchange. A higher GMP suggests strong demand for the IPO, while a lower GMP indicates weaker demand.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall investment strategy and market conditions. It's important to consider the company's fundamentals, growth prospects, and the broader market environment.
Who May Want to Wait
Investors who prefer stable and established companies may want to avoid IPOs like this, as they can carry higher risks associated with newer businesses. Those with low risk tolerance or a short investment horizon might find such investments unsuitable.
IPO Timeline, Explained
The IPO process includes several key dates: the opening date for subscription is on 12 May 2026, closing on 14 May 2026, with allotment scheduled for 15 May 2026 and listing on 19 May 2026.
Listing Gains — The Risk
Listing gains refer to the profit made by investors when they sell shares on the listing day at a higher price than the issue price. However, there are risks involved, including market volatility and the possibility that the stock may not perform well after listing, leading to potential losses.
This evaluation is generated from Goldline Pharmaceutical's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Goldline Pharmaceutical IPO GMP today?
Goldline Pharmaceutical IPO GMP today is +₹15.0 (34.88%), indicating an estimated listing price of ₹58. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Goldline Pharmaceutical IPO?
The price band of Goldline Pharmaceutical IPO is ₹41.0–₹43.0 per share.
When does Goldline Pharmaceutical IPO open and close?
Goldline Pharmaceutical IPO opens on 12 May 2026 and closes on 14 May 2026.
When does Goldline Pharmaceutical IPO list on the stock exchange?
Goldline Pharmaceutical IPO listed on 19 May 2026 at ₹58.0.
What is the lot size for Goldline Pharmaceutical IPO?
The lot size for Goldline Pharmaceutical IPO is 3000 shares, requiring a minimum investment of ₹258,000 (2 lots).
What is the price band for the Goldline Pharmaceuticals IPO?
The price band for the Goldline Pharmaceuticals IPO is ₹41.0 to ₹43.0.
What is the minimum investment required for this IPO?
The minimum investment required for this IPO is ₹258,000.
What is the lot size for the Goldline Pharmaceuticals IPO?
The lot size for the Goldline Pharmaceuticals IPO is 3000 shares.
When is the listing date for the IPO?
The listing date for the Goldline Pharmaceuticals IPO is 19 May 2026.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing price of an IPO based on unofficial trading.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
12 May 2026
Close
14 May 2026
Allotment
15 May 2026
Listing
19 May 2026
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Goldline Pharmaceutical?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.